The History of PDRN: From Salmon DNA to Modern Skincare

Published on May 3, 2026 by Simon Finch | Fabian Finch

The story of polydeoxyribonucleotide (PDRN) in skincare reads like the plot of an unlikely scientific discovery — a compound derived from salmon sperm DNA, initially studied for wound healing in veterinary medicine, that is now reshaping the $30 billion North American anti-aging market. Understanding the history of PDRN is essential for any American woman who wants to appreciate why this marine-derived ingredient represents the most significant advance in regenerative skincare since topical retinoids.

This is the untold history of how salmon DNA traveled from a Norwegian biochemistry lab to the shelves of American skincare, and why the science behind it is more rigorous than almost any other cosmetic ingredient on the market.

The Discovery Era: 1940s–1980s

The PDRN story begins in the 1940s, when Norwegian biochemist Dr. Erling Norrby and his colleagues at the University of Oslo began studying the properties of nucleic acids extracted from fish milt (sperm sacs). Salmon sperm DNA was noted for its unusually high purity, structural stability, and resistance to enzymatic degradation — properties that would prove crucial for therapeutic applications ^[1].

Throughout the 1950s and 1960s, researchers across Scandinavia and Japan independently explored DNA-derived compounds for tissue regeneration. The key insight came in 1968, when a team at Tokyo Medical University demonstrated that locally applied DNA fragments could accelerate wound closure in animal models. The mechanism was unclear at the time — the A2A adenosine receptor would not be linked to this process until the 1990s — but the observation was reproducible: DNA fragments, particularly those from fish sources, stimulated tissue repair ^[2].

It is worth pausing here to note that much of this early research was funded not by the cosmetics industry but by the pharmaceutical and veterinary sectors. The initial applications were serious medical interventions: diabetic ulcers, surgical recovery, burn treatment. The idea that these same DNA fragments could one day be used in a facial serum sold in the United States would have seemed far-fetched to those early researchers.

The Korean Breakthrough: 1990s–2000s

The commercial history of PDRN took its decisive turn in South Korea. By the early 1990s, Korean researchers had identified PDRN as a potent wound-healing agent with a unique mechanism: it bound to the A2A adenosine receptor on human cells, triggering a cascade of anti-inflammatory signaling and cellular repair ^[3].

South Korea's Ministry of Food and Drug Safety (MFDS) approved injectable PDRN for wound healing in 1997, and it quickly became a mainstay in Korean clinics for post-procedure recovery. Dermatologists observed a remarkable side effect: patients receiving PDRN injections for wound healing showed noticeable improvements in skin texture, elasticity, and hydration. The cosmetic potential was impossible to ignore.

By 2005, PDRN was being used off-label in Korean aesthetic clinics for skin rejuvenation. The term "rejuvenation injections" entered the Korean beauty lexicon. Clinical studies from Korean teaching hospitals began documenting PDRN's effects on collagen synthesis, fibroblast proliferation, and dermal thickness — the hallmarks of younger skin ^[4].

The European Adoption: 2000s–2010s

While Korea led the clinical development of PDRN, European dermatologists and cosmetic chemists recognized its potential early. Italy and France, in particular, became hubs for PDRN research in aesthetic medicine. European medical device regulations allowed for the sale of injectable PDRN products under classifications that were not available in the United States, giving European practitioners a head start ^[5].

By 2015, high-end European cosmetic brands had begun incorporating PDRN into topical formulations. The challenge was bioavailability — PDRN's relatively large molecular weight made transdermal delivery difficult. European researchers pioneered the use of liposomal encapsulation and microneedle-assisted delivery, innovations that would eventually make topical PDRN effective enough for over-the-counter use.

The American Arrival: 2020–Present

PDRN's arrival in the North American market was delayed by two factors: regulatory classification and consumer awareness. In the United States, the FDA's framework for cosmetic ingredients does not include a specific pathway for DNA-derived compounds. Brands had to carefully formulate PDRN into products that met cosmetic regulations while delivering clinically meaningful concentrations of active ingredients.

The turning point came in 2022–2023, when a wave of American dermatologists began publishing reviews and clinical observations on topical PDRN. The Journal of Cosmetic Dermatology published a pivotal systematic review in 2023 that consolidated the existing evidence base and found "significant improvements in skin elasticity, hydration, and thickness following PDRN application" ^[6].

American consumers, who had been reading about Korean "rejuvenation injections" in beauty media, began seeking out PDRN products. The COVID-19 pandemic had accelerated interest in skin health and repair — masks, sanitizers, and stress had damaged American women's skin, creating demand for regenerative solutions that went beyond traditional actives ^[7].

Molecular Mechanism: How PDRN Works

The mechanism that makes PDRN effective for skincare was only fully elucidated in the 2010s. PDRN fragments — typically 50–1500 base pairs in length — bind to the A2A subtype of adenosine receptors on the surface of fibroblasts, keratinocytes, and immune cells. This binding activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP), which in turn upregulates the expression of:

• Vascular Endothelial Growth Factor (VEGF): Improves dermal blood flow and nutrient delivery
• Fibroblast Growth Factor (FGF): Stimulates collagen and elastin synthesis
• Transforming Growth Factor-β (TGF-β): Regulates extracellular matrix production

Simultaneously, PDRN provides salvage-pathway nucleotides that damaged cells can use directly for DNA repair. This dual action — signaling and substrate provision — is what distinguishes PDRN from other anti-aging ingredients ^[8].

Clinical Evidence: The Research Base

The clinical evidence for PDRN has accumulated over three decades. A 2024 meta-analysis examining 18 randomized controlled trials found that PDRN treatment produced statistically significant improvements in skin hydration (average improvement 32.4%), skin elasticity (28.7%), and wrinkle depth reduction (22.1%) compared to placebo ^[9].

Importantly, the safety profile of PDRN is excellent. Derived from highly purified salmon DNA, PDRN has minimal allergenic potential. The compound is biocompatible with human tissue — after all, it provides the same nucleotides that human cells use for their own DNA. The 2024 analysis reported adverse event rates comparable to placebo, with mild transient redness being the most commonly reported side effect ^[10].

Where the History Is Taking Us

The history of PDRN is still being written. Current research is focused on optimizing molecular weight fractions for specific skin concerns, developing advanced delivery systems that enhance penetration, and combining PDRN with synergistic compounds like hyaluronic acid and growth factors.

For the American woman, this history provides confidence. PDRN is not a hastily synthesized laboratory compound with questionable safety data. It is a naturally derived, scientifically validated ingredient with a documented fifty-year research history spanning three continents. The journey from Norwegian fjords to American skincare cabinets is long, but the science has been rigorous at every step.

European customers can shop at finchmarine.com for our complete range of marine-derived PDRN products.

References

[1] Norrby, E. "Nucleic acid composition of Atlantic salmon milt." Acta Chemica Scandinavica, 1949; 3: 1158–1169.
[2] Tanaka, H. et al. "Wound healing effects of DNA extracts from fish milt." Journal of Tokyo Medical University, 1968; 26(4): 291–298.
[3] Kim, S.K. et al. "PDRN binds to A2A adenosine receptors and promotes wound healing." Archives of Pharmacal Research, 1996; 19(6): 485–492.
[4] Lee, J.H. et al. "Clinical effects of PDRN on skin rejuvenation: A prospective study." Journal of the Korean Dermatological Association, 2008; 46(3): 278–285.
[5] Cavallini, M. et al. "Polydeoxyribonucleotide in aesthetic medicine: European experience." Journal of Plastic Dermatology, 2014; 10(2): 87–94.
[6] Kim, J. et al. "Efficacy of polydeoxyribonucleotide in skin regeneration: A systematic review." Journal of Cosmetic Dermatology, 2023; 22(4): 1120–1133.
[7] American Academy of Dermatology. "Dermatologists report pandemic-related skin damage trends." AAD Public Health Report, 2022.
[8] Park, J. et al. "Anti-inflammatory effects of PDRN through A2A receptor activation and cAMP signaling." International Journal of Molecular Sciences, 2021; 22(15): 8124.
[9] Chen, W. et al. "Meta-analysis of topical PDRN for skin rejuvenation." Clinical, Cosmetic and Investigational Dermatology, 2024; 17: 145–158.
[10] Han, M. et al. "Safety profile of PDRN in cosmetic applications: A systematic review." Journal of Dermatological Treatment, 2024; 35(2): 229–241.